Enveric Biosciences Reports Year-End Progress For Preclinical Development Of Lead Prodrug Candidate EB-373; Enveric Expects To Finalize All Preclinical Activities Involving EB-373 In Q1 Of 2024 In Preparation For A First-in-human Clinical Trial
Portfolio Pulse from Benzinga Newsdesk
Enveric Biosciences has reported progress on the preclinical development of its lead prodrug candidate, EB-373, as of year-end. The company anticipates completing all preclinical activities for EB-373 by Q1 of 2024, setting the stage for a first-in-human clinical trial.
December 27, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences has announced significant progress in the preclinical development of EB-373, with expectations to complete these activities by Q1 2024, which is a positive step towards initiating first-in-human trials.
The news of progress in preclinical development is typically viewed positively by investors, as it indicates that the company is moving forward with its pipeline and is closer to potential revenue-generating products. The anticipation of completing preclinical activities by Q1 2024 suggests that the company is on track with its development timeline, which can be reassuring to investors. This progress could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100